Abstract
Background Recurrence rates following curative resection for hepatocellular carcinoma (HCC) remain persistently high, benefit from adjuvant immunotherapy varies substantially across patients, and the field currently lacks a standardized framework to characterize the postoperative host immune contexture.
Purpose To propose and validate a Multi-stage Precision Stratification (MPS) framework and evaluate its value in prognostic stratification and prediction of immunotherapy response.
Methods The Immune Health Index (IHI = S + R − E) integrating immune surveillance (S), immune exhaustion (E), and immune reserve (R) was constructed to define four immune phenotypes. Prognostic value was assessed in four public HCC cohorts (n=931) with single-cell transcriptomic validation (GSE140228, 61,690 cells); a blood-count-based clinical version cIHI_v8 was constructed in the Qinghai QPHCC cohort (n=490 survival analysis).
Results IHI was an independent protective prognostic factor in TCGA-LIHC (multivariate HR=0.795, P=0.034); four-cohort random-effects meta-analysis yielded HR=0.818 (95% CI: 0.696–0.961), I2=31.4%. QPHCC cIHI_v8 multivariate HR=0.452, HR=0.715 after ALBI adjustment; Bayesian evidence synthesis yielded BF_10=1280 for cIHI_v8 (>100 constitutes Decisive evidence), whereas the 4-cohort meta BF_10=2.19 (Anecdotal). Following NLP-based reverse stage derivation (n=490, achieving full AJCC/BCLC stage coverage from 0%), IHI remained significant after AJCC adjustment (HR=0.8642, P=0.000079), IHI provided positive incremental C-index across all stage-adjusted models; stratified analysis showed the strongest effect in early-stage (AJCC I-II: HR=0.8109, P<0.0001) and MVI-negative patients (HR=0.8538, P=0.0020). Bootstrap 1000× resampling: median HR=0.8646 (95% CI: 0.7985–0.9443), all iterations yielded HR<1.
Conclusions The MPS framework provides a mechanism-driven biological stratification tool for adjuvant immunotherapy in post-resection HCC, moving from “fixed-protocol extrapolation” to “immune contexture navigation.”
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Qinghai Red Cross Hospital gave ethical approval for this work (Approval No.: 2023-110). Written informed consent was waived by the Ethics Committee of Qinghai Red Cross Hospital due to the retrospective nature of the study and the use of de-identified clinical records from the hospital information system, in accordance with the Declaration of Helsinki. No prospective intervention was performed, no additional biological samples were collected, and no participants were re-contacted. Public cohort data (TCGA, ICGC, GEO) are derived from publicly available de-identified datasets that do not require additional ethics approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Co-first Author Contact: **Jianduojie Dan**, Department of Software Engineering, American University of Central Asia, Bishkek 720060, Kyrgyzstan. E-mail: danjianduojie{at}gmail.com;
Disclosure of Potential Conflicts of Interest: The authors declare no potential conflicts of interest.
Corresponding Author changed from Yamei Dang to Zhongfeng Dang. Author Cai Hao removed from the author list to ensure consistency between manuscript file and medRxiv submission. No scientific content changes.
Data Availability
Public cohort data (TCGA-LIHC, ICGC-LIRI-JP, GSE14520, GSE76427, GSE140228, GSE202145) are available from their respective repositories (GDC Portal, ICGC Data Portal, GEO). cBioPortal TCGA-LIHC real patient data were accessed via https://www.cbioportal.org. QPHCC de-identified clinical data are available upon reasonable request to the corresponding author, subject to institutional data governance policies of Qinghai Red Cross Hospital. Analysis code is available at https://github.com/zhongfeng-max/MPS_cIHI_v8_Evidence_Synthesis.
https://github.com/zhongfeng-max/MPS_cIHI_v8_Evidence_Synthesis
Data Availability Statement
The public datasets analyzed during the current study are available in the TCGA (https://portal.gdc.cancer.gov/) and GEO (https://www.ncbi.nlm.nih.gov/geo/) repositories under the accession numbers GSE14520, GSE76427, GSE140228, and GSE202145. The ICGC-LIRI-JP dataset was obtained from the official ICGC data portal (https://dcc.icgc.org/). The QPHCC cohort data (n=760 HCC patients, Qinghai Red Cross Hospital, 2015–2026) are not publicly available due to patient privacy protection, but de-identified processed intermediate datasets and the cIHI_v8 derivation code are available from the corresponding author upon reasonable request, subject to institutional data sharing agreements.
Funder Information Declared
